Typhoid Fever

Patent License Received on Oral Vaccine

Published in TB and Outbreaks Week, September 5th, 2000

Avant Immunotherapeutics, Inc. (AVAN), Needham, Massachusetts, announced the signing of a cross-licensing agreement with Megan Health Inc. for exclusive rights to a patent portfolio supportive of Avant's single-dose, oral vaccine candidate against typhoid fever, called Ty800.

The agreement allows Avant to further its clinical development of Ty800 in expanded Phase II studies, while Megan Health gains non-exclusive rights to use Avant's high-level expression system for human and non-human vaccines.

Fritz Casselman, Avant Immunotherapeutics, Inc., said: "We believe that Ty800 has strong potential to be an effective typhoid fever vaccine. If...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry